US 2023/0146568 A1 · FORMULATIONS WITH LIPID SYSTEMS CARRYING BIOACTIVE COMPOUNDS FOR USE AS AN IMMUNOTHERAPY POTENTIATOR OR ADJUVANT FOR PATIENTS WITH CANCER OR IMMUNOLOGICAL DISORDERS

Formulations with lipid systems carrying bioactive compounds for use as an immunotherapy potentiator or adjuvant for patients with cancer or immunological disorders

AssigneesUniversidad Autonoma De Madrid, Imdea Alimentacion, Hospital Universitario Infanta Sofia

InventorsCarlos TORRES OLIVARES, Luis VÁZQUEZ DE FRUTOS, Marta CORZO, Pablo ARRANZ, Ana RAMÍREZ DE MOLINA, Guillermo REGLERO RADA, Viviana LORIA KOHEN, Marta GÓMEZ DE CEDRÓN, Juan MORENO RUBIO, José Moisés LAPARRA LLOPIS, Enrique CASADO SÁENZ

Life of this patent

Estimating the term…

Abstract

The present invention relates to a lipid system which not only improves stability during digestion and oral bioavailability of various bioactive compounds in a safe and effective manner, but also in many cases enhances the effects of said compounds. The present invention also relates to formulations or compositions comprising lipid systems carrying bioactive compounds for use as immunotherapy potentiators or adjuvants for patients with cancer or immunological disorders.

Claims16

Dependent claims

A composition comprising a supercritical rosemary extract (SRE) and a lipid system in turn comprising ratfish liver oil (RLO) or the product of an enzymatic or chemical glycerolysis process based on ratfish liver oil (RLO).

Dependencies are inferred from the claim text.

Facts

Application

17/941,925Filed 9 Sep 2022

Priority

ES P20163056029 Apr 2016

Published

11 May 2023

Term ends

Not estimatedThe source records don’t support an estimate.

Classification16 codes

A23L 33/105
Using additives: plant extracts, their artificial duplicates or their derivatives
A23L 33/115
Using additives: fatty acids or derivatives thereof; Fats or oils
A61K 9/0014
Galenical forms characterised by the site of application: skin, i.e. galenical aspects of topical compositions
A61K 9/0053
Galenical forms characterised by the site of application: mouth and digestive tract, i.e. intraoral and peroral administration